Explore Stanford technologies available for licensing:

To date, there are no treatments to restore neurologic function for the 7 million US patients suffering from chronic ischemic stroke. NR1 therapy provides a novel treatment for this unmet need.

Stanford scientists have discovered a new immunotherapeutic target for treating lung cancer and fibrotic lung disease.

Determining a patient's drug susceptibility is currently a lengthy process requiring hundred to millions of cells. Currently, these cells are labelled, frozen or otherwise manipulated in ways that prevent sequential testing against multiple drugs on the same few cells.

Stanford researchers in the Snyder lab have discovered and developed an innovative immunoglobulin modality for the treatment of insulin resistance and type 2 diabetes.

The Zhenan Bao Research Group at Stanford University developed and manufactured a photo-curable, directly patternable, stretchable, and highly conductive polymer that is ideal for bioelectronic applications, and stretchable electronic devices.

The Problem: Chronic pain is best treated with a 'whole-person' approach that include behavioral/psychological approaches to pain self-management.

Researchers at Stanford University have identified a small molecule tryptase inhibitor for treatment of severe allergies. Mast cells are a part of the innate and adaptive immune response. Mast Cell activation results in release of granules containing tryptases.

Exhausted T cells are T cells that become dysfunctional after a period of time and play a role in reduced efficacy of T cell targeted immunotherapies.

Stanford researchers in the Heilshorn lab have developed injectable, cell-compatible hydrogels with tunable release of therapeutic cargo.

Stanford researchers in the WE3 and S3 Labs developed a cloud-based computation and predictive control platform for wastewater treatment facilities energy storage and energy generation. Wastewater treatment is energy and cost intensive.

Dr. Curt Scharfe and colleagues have developed RUSPseq, a method for next generation molecular testing originally conceived to diagnose metabolic disorders in newborns.

Researchers at Stanford University have developed a rapid and sensitive bioluminescent assay for screening bacterial infections using enzyme-produced photo emission for detection of beta lactamase activity.

Stanford researchers in The Tang Group have developed a reproducible, high throughput device that dices tissue into uniformly sized sub-millimeter sample fragments.

A common hurdle for many drug delivery applications is getting the desired compounds to the targeted cells or receptors. Additional barriers of achieving the therapeutic drug concentration and necessary drug diffusion are also present even after successful targeted delivery.

Disease indication - Oncology/solid tumors, notably glioblastoma

Drug format - Engineered peptide for cancer vaccine optimization.

Drug class - Improvement to existing vaccine.